Carter has previously been responsible for increasing retail sales and negotiating new sales opportunities for a number of international pharmacy companies including AAH Pharmaceuticals and Mylan. She has also worked as a prescribing technician for Central Cheshire Primary Care Group.
The company says Carter’s industry credentials and experience of working in both hospital and retail pharmacy will enable the firm to extend its partnerships with hospitals and dispensing doctors.
Quantum appoints national account manager
Pauline Carter brings 18 years’ experience to the role
You may also like
Finance
![Aplagon closes €4.8m round to advance first-in-class antithrombotic APAC into Phase II AVF trial]()
Aplagon closes €4.8m round to advance first-in-class antithrombotic APAC into Phase II AVF trial
The financing supports a European CTA filing with the EMA for arteriovenous fistula maturation failure in end-stage kidney disease, expanding APAC's clinical programme across thrombo-inflammatory indications
Manufacturing
![AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn]()
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance
![GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors]()
GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors
GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
